Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

Medications to treat HIV are effective, but not curative. Now researchers at Johns Hopkins say they’re working on a new treatment – and it’s one already in use for cancer patients. They are very ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are ...

In 1981, physicians in Los Angeles reported five young patients with Pneumocystis pneumonia, a rare lung infection later recognized as the first sign of HIV infection and a defining illness of AIDS.

An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

CLEVELAND, Ohio (WOIO) - Dr. Saba Valadkhan is a professor at Case Western Reserve University in Cleveland. But the next time you see her, it could be in history textbooks. Her extensive research on a ...

A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability that could lead to new therapies and bring the world closer to a ...

Innovation has been driving progress in the HIV response for decades. The introduction of combination antiretroviral therapy in the 1990s meant living with HIV was no longer a death sentence.

Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...

People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus for certain participants in recent trials in Africa and Europe A digital ...